Evidence map›Paper›PMID 27308827›Full record

ArticlePloS one2016

A Modified Glycosaminoglycan, GM-0111, Inhibits Molecular Signaling Involved in Periodontitis.

Justin R Savage, Abigail Pulsipher, Narayanam V Rao, Thomas P Kennedy, Glenn D Prestwich, Maria E Ryan, Won Yong Lee

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Effect of xylitol on Porphyromonas gingivalis: A systematic review.Clinical and experimental dental research · 2023
    Pooled it
  2. Hyaluronic Acid in Rhinology: Its Uses, Advantages and Drawbacks-A Review.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. [Effect of injectable composites of calcium sulfate and hyaluronate in enhancing osteogenesis].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2017
    Article
  13. Prevention of sinonasal inflammation by a synthetic glycosaminoglycan.International forum of allergy & rhinology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Justin R SavageGlycoMira Therapeutics, Inc. Salt Lake City, UT, 84108, United States of America.
Abigail PulsipherGlycoMira Therapeutics, Inc. Salt Lake City, UT, 84108, United States of America.
Narayanam V RaoGlycoMira Therapeutics, Inc. Salt Lake City, UT, 84108, United States of America.
Thomas P KennedyGlycoMira Therapeutics, Inc. Salt Lake City, UT, 84108, United States of America.
Glenn D PrestwichGlycoMira Therapeutics, Inc. Salt Lake City, UT, 84108, United States of America.
Maria E RyanDepartment of Oral Biology and Pathology, School of Dental Medicine, Stony Brook University, Stony Brook, NY, 11794, United States of America.
Won Yong LeeGlycoMira Therapeutics, Inc. Salt Lake City, UT, 84108, United States of America.
GlycoMira Therapeutics (United States) · USStony Brook University · US

Funding

Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of PeriodontitisR44DE022216 · NIDCR · GLYCOMIRA, LLC · PI LEE, WON YONG, PRESTWICH, GLENN DOWNES · 2013 to 2015
$1.5M
Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral MucositisR44DE024024 · NIDCR · GLYCOMIRA, LLC · PI LEE, WON YONG · 2016 to 2017
$746k
Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral MucositisR43DE024024 · NIDCR · GLYCOMIRA, LLC · PI LEE, WON YONG · 2014 to 2014
$200k
NIDCR NIH HHS R43 DE024024NIDCR NIH HHS R44 DE022216NIDCR NIH HHS R44 DE024024
6 · The paper itself

Abstract

backgroundPeriodontitis is characterized by microbial infection, inflammation, tissue breakdown, and accelerated loss of alveolar bone matrix. Treatment targeting these multiple stages of the disease provides ways to treat or prevent periodontitis. Certain glycosaminoglycans (GAGs) block multiple inflammatory mediators as well as suppress bacterial growth, suggesting that these GAGs may be exploited as a therapeutic for periodontitis.

methodsWe investigated the effects of a synthetic GAG, GM-0111, on various molecular events associated with periodontitis: growth of Porphyromonas gingivalis (P. gingivalis) and Aggregatibacter actinomycetemcomitans (A. actinomycetemcomitans) pathogenic bacteria associated with periodontitis; activation of pro-inflammatory signaling through TLR2 and TLR4 in mouse macrophage RAW 264.7 cells and heterologously expressed HEK 293 cells; osteoclast formation and bone matrix resorption in cultured mouse pre-osteoclasts.

results(1) GM-0111 suppressed the growth of P. gingivalis and A. actinomycetemcomitans even at 1% (w/v) solution. The antibacterial effects of GM-0111 were stronger than hyaluronic acid (HA) or xylitol in P. gingivalis at all concentrations and comparable to xylitol in A. actinomycetemcomitans at ≥2% (w/v) solution. We also observed that GM-0111 suppressed biofilm formation of P. gingivalis and these effects were much stronger than HA. (2) GM-0111 inhibited TLR-mediated pro-inflammatory cellular signaling both in macrophage and HEK 293 cells with higher selectivity for TLR2 than TLR4 (IC50 of 1-10 ng/mL vs. > 100 μg/mL, respectively). (3) GM-0111 blocked RANKL-induced osteoclast formation (as low as 300 ng/mL) and bone matrix resorption. While GM-0111 showed high affinity binding to RANKL, it did not interfere with RANKL/RANK/NF-κB signaling, suggesting that GM-0111 inhibits osteoclast formation by a RANKL-RANK-independent mechanism.

conclusionsWe report that GM-0111 inhibits multiple molecular events involved in periodontitis, spanning from the early pro-inflammatory TLR signaling, to pathways activated at the later stage component of bone loss.

Indexed as

Aggregatibacter actinomycetemcomitansAnimalsAnti-Inflammatory Agents, Non-SteroidalBinding SitesBiofilmsBone Density Conservation AgentsCell LineGene ExpressionGlycosaminoglycansHEK293 CellsHumansMacrophagesMiceNF-kappa BOsteoblastsOsteoclastsAnti-Inflammatory Agents, Non-SteroidalBone Density Conservation AgentsGlycosaminoglycansNF-kappa BRANK LigandReceptor Activator of Nuclear Factor-kappa BTlr2 protein, mouseTlr4 protein, mouseTnfrsf11a protein, mouseTnfsf11 protein, mouseToll-Like Receptor 2Toll-Like Receptor 4

Identifiers

PMID27308827
PMCPMC4911086
OpenAlexW2430235667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.